SWK Holdings

Impedimed Limited is a medical software technology company based in Pinkenba, Australia, specializing in the development, manufacturing, and distribution of bioimpedance spectroscopy (BIS) devices and software services. The company offers a range of noninvasive devices, including SOZO, which is designed for detecting lymphedema and monitoring fluid status in heart failure patients, as well as SFB7, which analyzes body composition in healthy individuals. Additionally, ImpediMed provides ImpediVET, a BIS device tailored for veterinary applications. The company's products cater primarily to hospitals and clinics across Australia, North America, and other international markets. Founded in 1999, Impedimed is committed to advancing medical technology for clinical assessments and monitoring of fluid status and tissue composition, while also offering a cloud-based platform for managing patient data.

Journey Medical Corporation is a commercial-stage pharmaceutical company specializing in the development, acquisition, licensing, and commercialization of branded dermatology products. As a subsidiary of Fortress Biotech, Inc., Journey Medical has launched four products since 2016 and currently offers a portfolio that includes eight branded and three authorized generic prescription drugs aimed at treating various dermatological conditions. Notable products in its lineup include Qbrexza, Accutane, Amzeeq, and Exelderm, all marketed within the United States.

Shield Therapeutics is an independent specialty pharmaceutical company based in Wollerau, Switzerland, concentrating on the development and commercialization of late-stage, mineral-derived pharmaceuticals aimed at addressing significant unmet medical needs. The company’s primary focus is on its lead product, Feraccru, which is designed for the treatment of iron deficiency anemia associated with inflammatory bowel disease, as well as chronic kidney disease. Additionally, Shield Therapeutics is advancing PT20, a product intended for the management of hyperphosphatemia, which is nearing the final stages of development. The company generates most of its revenue from the Feraccru segment.

Elutia is a commercial-stage regenerative medicine company dedicated to developing innovative products aimed at enhancing patient outcomes during surgical procedures, particularly for those receiving implantable medical devices. The company focuses on several key areas, including Device Protection, Women's Health, and Cardiovascular health, with the Women's Health segment generating the highest revenue. Utilizing proprietary tissue processing platforms, Elutia has created a range of advanced regenerative medical products that closely resemble natural biological materials. These products are designed to address unmet clinical needs by promoting healthy tissue formation and minimizing complications commonly associated with medical device implants, such as scar tissue formation and capsular contraction.

MedMinder Systems, Inc. specializes in developing products for pill dispensing, medication management, and adherence support. The company offers a range of solutions including automatic pill dispensers that provide reminders through visual and auditory alerts, as well as notifications for caregivers and family members to monitor medication usage remotely. MedMinder's product lineup includes locked pill dispensers, medical alert devices, and pre-filled trays designed for various forms of medication such as pills and capsules. Established in 2007 and headquartered in Needham, Massachusetts, MedMinder serves customers across several states including Massachusetts, New York, Florida, and Pennsylvania, among others. The company's mission is to simplify the medication management process and enhance adherence for users.

Advanced Oxygen Therapy specializes in advanced wound care products that employ patented non-invasive Topical Wound Oxygen (TWO2) therapy. This innovative approach is designed to facilitate the healing of various wound types, particularly chronic wounds such as diabetic, pressure, and venous ulcers, as well as acute wounds including post-surgical, cosmetic, and burn injuries. TWO2 therapy effectively addresses the underlying causes of chronic wound failure by reversing tissue hypoxia, stimulating cellular mechanisms necessary for tissue regeneration, providing non-contact sequential compression to reduce edema and enhance perfusion, and creating an environment that eliminates harmful pathogens. By successfully treating previously unresponsive wounds, this therapy can save limbs, lower overall healthcare costs, and significantly enhance patients' quality of life. Advanced Oxygen Therapy's products, including the TWO2 Extremity Chamber and TWO2 Multi-Patch, are available for both institutional and home care settings, promoting the health and independence of patients globally.

Acer Therapeutics Inc. is a pharmaceutical company dedicated to the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. Founded in 2013 and headquartered in Newton, Massachusetts, the company has a diverse clinical pipeline that includes several promising candidates. EDSIVO is designed for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation. ACER-001, a taste-masked formulation of sodium phenylbutyrate, targets various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. Additionally, Acer is developing osanetant for the treatment of induced vasomotor symptoms and has initiated research on emetine hydrochloride as a potential COVID-19 treatment in collaboration with the National Center for Advancing Translational Sciences. The company also holds a license agreement with Sanofi for worldwide rights to osanetant.

MolecuLight specializes in innovative imaging solutions for wound care, particularly in the detection of harmful bacteria and the measurement of wounds. The company develops portable handheld optical imaging devices that allow medical practitioners to visualize bacteria and assess tissue viability at the point of care. These devices facilitate the documentation and monitoring of wound healing progress, enabling healthcare professionals to select the appropriate therapy for their patients in a timely manner. By providing accurate analysis and procedural guidance, MolecuLight's technology aims to enhance patient outcomes in wound management.

Trio Healthcare Limited, founded in 2006 and based in Skipton, United Kingdom, develops and supplies medical solutions for the healthcare and veterinary markets. The company specializes in products for stoma care, continence management, and wound care, offering a range of silicone-based accessories designed to be gentle on the skin. Its product lineup includes seals, sprays, wipes, gels, and flanges, which utilize breathable silicone technology to promote healthy skin around stomas. Trio Healthcare also provides veterinary solutions to address the needs of pet owners and veterinary professionals. The company is dedicated to improving patient outcomes through innovative healthcare solutions.

4WEB Inc. is a Frisco, Texas-based company that specializes in the development and manufacturing of 3D-printed titanium implant devices for the healthcare industry. Founded in 2008, the company focuses on orthopedic solutions, particularly in the spine, foot, and ankle sectors. Its product line includes various systems such as the Posterior Spine Truss System and Anterior Spine Truss System, which utilize a novel geometry known as "4WEB." This innovative design enhances strength and promotes bone healing by facilitating optimal load transfer and osseous incorporation. The company's implants aim to support structural integrity in orthopedic procedures, providing an effective alternative to traditional biologics. Initially concentrated on spine implants, 4WEB has expanded its technology to address a wider range of orthopedic applications, offering comprehensive surgical solutions for neurosurgeons and orthopedic surgeons alike.

Epica International, Inc. specializes in designing, developing, and distributing advanced robotic systems aimed at enhancing precision and outcomes in various medical fields. The company's product lineup includes Vimago, a CT imaging and fluoroscopy device for veterinary diagnostics; Pegaso, a high-definition CT system for equine veterinary applications; and Artemis, a device for non-invasive regenerative therapy in animals. Additionally, Epica offers Ortis, a carving robotic system for orthopedic applications, and SandRob, a surface processing system for detailed finishing needs. Their ScultoRob system is designed for milling artistic and architectural designs, while ARPP serves as a robotic simulation software for control and programming. Founded in 2013 and based in San Clemente, California, Epica International aims to integrate precision robotics with imaging technologies to improve diagnostic and therapeutic capabilities in veterinary medicine, orthotics, and surface processing markets.

Parnell Living Science is a veterinary pharmaceutical company that focuses on developing innovative health solutions for animals. Based in Sydney, Australia, the company offers a range of products including GLYDE, a nutraceutical designed to protect and treat osteoarthritis in dogs, as well as disease-modifying osteoarthritis drugs and non-steroidal anti-inflammatory drugs that alleviate related symptoms. In addition to its canine offerings, Parnell provides treatments for degenerative joint diseases in horses and develops products for various therapeutic areas, including anesthesia, anti-inflammatories, and anti-infectives for companion, production, and performance animals. With a commitment to high-quality standards and a fully integrated manufacturing facility, Parnell serves the pastoral industry primarily in Australia, while also expanding its operations internationally. The company is focused on continuing to innovate and bring new products to market, particularly for the companion animal sector.

SynCardia Systems, Inc. is a medical technology company based in Tucson, Arizona, established in 2001. The company specializes in the development, manufacturing, and commercialization of the SynCardia temporary Total Artificial Heart (TAH-t), an implantable device designed to replace the function of a failing human heart in patients with advanced heart failure. The TAH-t serves as a critical bridge to heart transplantation, enabling patients to survive until a suitable donor heart becomes available. SynCardia operates primarily in the United States, European Union, and Canada, addressing a significant need in the field of cardiac care.

KANA Software, Inc., a wholly owned subsidiary of Verint, specializes in providing Customer Engagement Optimization solutions tailored for Fortune 500 companies, mid-market businesses, and government agencies. The company offers three primary product lines: KANA Enterprise, which unifies agent and customer experiences across multiple channels and integrates legacy systems; LAGAN Enterprise, designed to address the complex data management needs of the public sector, including non-emergency call centers; and KANA Express, a cloud-based solution that delivers integrated multi-channel customer service for mid-size businesses and government entities. All product offerings feature capabilities such as a unified agent desktop, integrated knowledge management, email and live chat management, web self-service, social media management, and comprehensive reporting and analytics, ensuring a seamless interaction experience for both agents and customers.

eVergance Partners provides customer relationship management strategy, transformation, and implementation consulting services.